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Abstract
Background: Diabetes mellitus (DM) is a significant factor regarding poor outcome in
patients with myocardial infarction. Recently a new prognostic factor is under consideration
— a baseline glucose level on admission. We sought to assess the influence of blood glucose
levels on admission on prognosis of patients with acute ST-segment elevation myocardial
infarction (STEMI) treated with percutaneous coronary intervention (PCI).
Methods and results: Consecutive patients treated with PCI for STEMI were analyzed.
Presence or absence of DM was the first grouping criterion. The secondary criterion was the
blood glucose level on admission [threshold ≥ 7.8 mmol/L (140 mg/dL)]. Hyperglycemic and
non-hyperglycemic subgroups were selected within both DM and non-DM groups according to
the threshold. One-year mortality of diabetics was 16.0%. There was no significant difference
in 1-year mortality between hyperglycemic and non-hyperglycemic patients with DM. One-year
mortality in the non-DM group was 5.6%. Patients without DM but with hyperglycemia showed
a higher 1-year mortality rate than non-hyperglycemic patients (8.51% vs. 3.68%, p = 0.001).
Multivariate analysis revealed that in the non-DM group blood glucose level (per 1 mmol/L) on
admission was a factor affecting 1-year mortality [HR = 1.09 (1.01–1.17)].
Conclusions: Elevated blood glucose levels in STEMI affect the prognosis of patients without
DM; however, it is not an independent death risk factor of patients with DM treated with PCI.
(Cardiol J 2008; 15: 422–430)
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Introduction
The incidence of diabetes mellitus (DM) in
patients hospitalized with myocardial infarction ran-
ges between 10% and 20% and is rising [1–4]. It has
been proven that DM is an independent prognostic
factor in patients with coronary heart disease [5].
Patients with diabetes and myocardial infarction
have greater incidence of major adverse cardiova-
scular events (MACE) and higher in-hospital and
long-term mortality [1, 2, 6, 7]. The prognostic si-
gnificance of blood glucose abnormalities in patients
with DM has also been suggested. It has been de-
monstrated that the higher the blood glucose level,
the higher the short- and long-term mortality [8–10].
On the other hand, there are some reports contra-
dicting this relationship [11, 12]. Such divergent
conclusions may be due to group heterogeneity (pa-
tients with all types of acute coronary syndromes),
or varying definitions of hyperglycemia cut-off va-
lues and different treatment methods (the relation-
ship has been confirmed primarily in myocardial
infarction treated with fibrinolytic therapy) [8–13].
High blood glucose levels in acute myocardial in-
farction may also affect the prognosis of patients
without DM [12, 14–18]. The problem of analyzed
group heterogeneity and differing hyperglycemia
thresholds is the burden of studies analyzing the
influence of glucose levels on the prognosis of pa-
tients with myocardial infarction without DM
[11, 12, 14]. However, the fact, that the prognosis
of patients without diagnosis of DM but with incre-
ased blood glucose in acute myocardial infarction
phase is similar or even worse than patients with
DM is interesting [14, 15, 19].
Considering the divergent report results on the
prognostic influence of blood glucose level and he-
terogeneity of analyzed groups, we decided to as-
sess this effect in a group with acute ST-segment
elevation myocardial infarction (STEMI) treated
with percutaneous coronary intervention (PCI).
Methods
Patients
We analyzed consecutive patients presenting
with acute STEMI admitted to the 3rd Chair and De-
partment of Cardiology of the Silesian Centre for
Heart Diseases in Zabrze, Poland. The following
patients were referred for urgent invasive diagno-
stics with the intention of performing PCI: with
persistant (≥ 30 min) retrosternal pain, electrocar-
diographic features of acute myocardial infarction,
i.e. ST segment elevation ≥ 0.1 mV in two or more
limb leads or ST ≥ 0.2 mV in two or more pericar-
dial leads, or acute left bundle branch block, with
chest pain duration to invasive treatment below
12 hours, and who gave written consent to participa-
te in the study. The patients after unsuccessful
fibrinolytic therapy were also referred for PCI. To
sum up, the patients were treated with primary and
rescue PCI. Patients with pulmonary edema or car-
diogenic shock were excluded from the study. All
patients received 300–500 mg of oral acetylsalicy-
lic acid, 5.000–10.000 IU of heparin and 5 mg of
morphine intravenously, provided the drugs had not
been given earlier. In addition, in case of additional
indications the following medications were admini-
stered: nitroglycerin, beta-blocker, angiotension-
converting enzyme inhibitor, antiarrhythmic drugs
or atropine. The coronary angiography was perfor-
med by femoral artery puncture. The epicardial ar-
tery flow was assessed according to thrombolysis
in myocardial infarction (TIMI) scoring [20]. After
angiography, the patients eligible for stenting re-
ceived clopidogrel 300 mg. Depending on the cour-
se and duration of the procedure, additional hepa-
rin doses were administered at the operating phy-
sician’s discretion. PCI procedure with TIMI 3 flow
and residual stenosis £ 30%, without features of
dissection limiting the flow in the artery, was con-
sidered effective. After the procedure, the patients
were transported to the Cardiology Care Unit. All
patients received oral acetylsalicylic acid 150 mg
once daily. Administration of beta-blockers, angio-
tension converting enzyme inhibitors and statins
were recommended unless contraindications were
present. All diabetic and non-diabetic patients with
hyperglycemia in the acute phase of STEMI were
treated with short-acting insulin given as an infu-
sion or subcutaneous injections. Following acute
myocardial infarction and at discharge, if daily de-
mand for insulin was lower than 30 units, the treat-
ment used before myocardial infarction was applied.
If DM was diagnosed in hospital following the acu-
te phase of myocardial infarction and daily demand
for insulin was lower than 30 units, oral hypoglyce-
mic agents or diet were used. Otherwise, intensi-
ve insulin therapy was continued. Patients received
150 mg of ticlopidine orally twice daily for 8 weeks
after stenting. In the case of pain recurrence with
concomitant ST segment elevation, all such patients
were referred for urgent repeat coronary angiogra-
phy with re-PCI if reclusion or significant infarct-
related artery (IRA) stenosis were found. Data con-
cerning clinical and angiographic characteristics,
and in-hospital and 1-year prognosis were recorded
on the database. Data concerning 1-year follow-up
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were gathered using questionnaires, telephone calls
and information gained from the National Health
Fund Register, including hospitalizations, reasons
for hospitalization and procedures performed. Data
that were gathered using questionnaires and tele-
phone calls were verified in the National Health
Fund Register, so the final percentage of follow-up
was 100%.
The study was approved by the local bioethical
committee and all patients gave their informed consent.
Blood glucose level on admission and
diabetes mellitus diagnosis. Group selection
Blood glucose levels were detected using ve-
nous blood at the time the patient was admitted to
the hospital and on the following days of hospitali-
sation, as requested by the attending physician. The
presence or absence of DM was the first grouping
criterion. Group 1 consisted of patients who were
assumed to have diabetes, if previous diagnosis of
DM (documented DM treated with insulin or oral
anti-diabetic drugs or diet) or newly diagnosed DM
during hospital stay was stated. The criterion of
newly diagnosed DM were as follows: fasting blo-
od glucose ≥ 7 mmol/L (126 mg/dL) stated at least
twice after acute phase of myocardial infarction or
blood glucose ≥ 11.1 mmol/L (200 mg/dL) stated
in 2-hour glucose tolerance test done at the end of
the hospitalization period. Group 2 consisted of pa-
tients without diagnosis of DM. The secondary gro-
uping criterion was blood glucose level on admission.
All patients had venous blood drawn for glucose
on admission. Blood glucose level ≥ 7.8 mmol/L
(140 mg/dL) was considered as hyperglycemic. Accor-
ding to this threshold, there were hyperglycemic
and non-hyperglycemic subgroups isolated from
both DM and non-DM groups.
Endpoints
One-year mortality was selected as the prima-
ry endpoint. The relationship between blood glu-
cose on admission and 1-year mortality was analy-
zed in the groups with and without DM separately.
Subsequently, multivariate analysis was performed
to identify independent predictors of mortality. The
secondary endpoint was the percentage rate of in-
hospital mortality, in-hospital and 1-year stroke,
reinfarction and MACE in 1-year follow-up. MACE
was defined as composite endpoint of stroke, myo-
cardial infarction and death.
Statistical analysis
Continuous parameters with normal distribution
were presented as mean ± standard deviation (SD).
The significance of mean differences was tested
with a t-Student test. Qualitative parameters were
compared with the c2 test (with Yates correction in
cases of expected size below 5). To analyze the re-
lationship between the parameters and mortality,
a Cox proportional hazard regression model was
used; the results were presented as hazard ratio
(HR) and 95% confidence interval (CI). Statistically
significant p-levels were assumed as < 0.05 (two-
sided). In this analysis, admission glucose concen-
tration was used as a continuous variable. Statistical
calculations and analyses were performed with Sta-
tistical PL software version 6.1 by StatSoft, Inc.
Results
There were 1,310 consecutive patients admit-
ted who met inclusion criteria and underwent PCI.
The study group included 352 (26.9%) patients with
DM and 958 (73.1%) patients without DM.
Patients with diabetes mellitus
Clinical particulars. In the group with DM,
blood glucose level on admission ≥ 7.8 mmol/L
(140 mg/dL) was found in 289 (82.1%) patients,
while blood glucose level < 7.8 mmol/L (140 mg/dL)
was seen in 63 (17.9%) patients. The mean blood
glucose was: 14.07 mmol/L (253.26 mg/dL) and
6.33 mmol/L (113.94 mg/dL) in hyperglycemic and
non-hyperglycemic subgroups, respectively. Hy-
perglycemia was seen more in older patients and
patients with hypertension, and the majority of the
patients were female. Clinical particulars are pre-
sented in Table 1.
Angiographic particulars. In angiography,
there was a strong trend towards higher multives-
sel disease prevalence in the hyperglycemic sub-
group than in the non-hyperglycemic subgroup; the
figures were 63.67% vs. 50.79%, respectively. The
IRA distribution was similar in both subgroups.
Likewise, the initial IRA TIMI 2–3 flow, final TIMI-3
flow, stenting and reocclusion rates did not differ
significantly between the groups. Angiographic data
are presented in Table 2.
In-hospital and 1-year follow-up. Maximum
creatinine kinase concentration, hemorrhagic com-
plications, the need of urgent coronary artery by-
pass grafting (CABG), left ventricular ejection frac-
tion, stroke rate and mean time of hospitalization
did not differ significantly, regardless of blood glu-
cose on admission. In-hospital mortality in the DM
group was 8.2%. Rates of stroke, myocardial rein-
farction and death in 1-year follow-up were also
comparable in both subgroups. One-year mortality
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of DM patients was 16.0%. The data on in-hospital
and 1-year follow-up are presented in Table 3.
Predictors of higher 1-year mortality.
Multivariate analysis. Multivariate analysis of
patients with DM proved that decreased left ventri-
cular ejection fraction and worse initial IRA flow
(TIMI 0–1) were independent predictors of 1-year
mortality. Moreover, there was a distinct trend sug-
gesting a relationship between age and mortality. The
blood glucose level on admission (per 1 mmol/L) was
not an independent risk factor of higher 1-year mor-
tality (HR=1.03; 95% CI 0.98–1.07; p = 0.27). The
results of multivariate analysis are listed in Table 4.
Patients without diabetes
Clinical particulars. In the group without
DM, 378 (39.5%) patients had blood levels on admis-
sion ≥ 7.8 mmol/L (140 mg/dL), while blood glucose
Table 1. Clinical characteristics of the analyzed groups.
Parameters Patients with diabetes mellitus Patients without diabetes mellitus
                               Blood glucose level p                     Blood glucose level p
< 7.8 mmol/L  ≥ 7.8 mmol/L  < 7.8 mmol/L ≥ 7.8 mmol/L
(140 mg/dL)   (140 mg/dL)  (140 mg/dL)   (140 mg/dL)
Age [years] 58.42 ± 11.59 62.48 ± 9.85 0.01 55.62 ± 10.5 59.01 ± 10.65 0.000002
Females [%] 31.75 44.64 0.06 19.66 25.9 0.02
Hypertension [%] 60.32 72.66 0.05 46.21 51.85 0.088
Hyperlipidemia [%] 60.53 60.00 0.95 61.99 60.14 0.62
Smokers [%] 53.97 48.96 0.47 75.82 63.76 0.00006
Prior MI [%] 17.46 24.57 0.22 17.24 15.08 0.37
Mean blood glucose 6.33 ± 1.07 14.07 ± 4.57 0.000001 6.36 ± 0.96 9.91 ± 2.35 0.000001
level on admission (113.94 ± (253.26 ± (114.48 ± (178.38 ±
[mmol/L] (mg/dL) ± 19.26) ± 82.26) ± 17.28) ± 42.30)
Time from onset 6.10 ± 7.80 5.48 ± 4.76 0.54 4.9 ± 3.4 4.1 ± 2.6 0.00007
of symptoms to PCI [h]
Anterior infarction [%] 41.27 43.25 0.77 39.14 39.42 0.93
Fibrinolytic therapy 20.63 25.26 0.43 20.52 26.72 0.02
before PCI [%]
PCI — percutaneous coronary intervention; MI — myocardial infarction
Table 2. Angiographic characteristics of the analyzed groups.
Parameters Patients with diabetes mellitus Patients without diabetes mellitus
                                Blood glucose level p                      Blood glucose level p
< 7.8 mmol/L ≥ 7.8 mmol/L < 7.8 mmol/L ≥ 7.8 mmol/L
(140 mg/dL)    (140 mg/dL) (140 mg/dL)    (140 mg/dL)
Infarction-related 0.30 0.20
artery [%]
Right coronary artery 39.68 41.87 40.34 45.50
Circumflex coronary 19.05 13.84 17.93 12.96
artery
Left anterior descending 39.68 43.94 41.21 41.27
coronary artery
Left main coronary artery 1.59 0.35 0.52 0.26
Initial TIMI 2–3 flow [%] 34.92 28.72 0.32 35.52 31.48 0.19
Multivessel coronary 50.79 63.67 0.057 48.44 55.82 0.02
disease [%]
TIMI 3 flow after PCI [%] 84.13 90.66 0.12 92.93 91.27 0.34
Stenting [%] 65.08 74.39 0.13 72.24 74.07 0.52
Reocclusion [%] 7.89 8.50 0.90 3.86 6.38 0.12
PCI — percutaneous coronary intervention; TIMI — thrombolysis in myocardial infarction
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levels < 7.8 mmol/L (140 mg/dL) were determined
in 580 (60.5%) patients. Mean blood glucose levels
in the hyperglycemia subgroup was 9.91 mmol/L
(178.38 mg/dL) and in the non-hyperglycemia sub-
group, 6.36 mmol/L (114.48 mg/dL). Patients with hy-
perglycemia were approximately 3.5 years older, and
there were more females and fewer smokers among
them. The mean duration of time from onset of symp-
toms to PCI in the hyperglycemia subgroup was shor-
ter (4.1 h vs. 4.9 h). What is more, there were more
patients after ineffective fibrinolytic therapy in this
subgroup. Moreover, the hyperglycemic subgroup
presented a tendency to be hypertensive more often.
Clinical particulars are presented in Table 1.
Angiographic particulars. Patients with hy-
perglycemia on admission had concomitant multives-
sel coronary heart disease more frequently, which
occurred in both hyperglycemic and non-hypergly-
cemic subgroups (55.82% vs. 48.44%, respectively).
However, there were no significant differences in
angiographic infarction localization, initial IRA TIMI
2–3 flow, final TIMI 3 flow, and stenting and reoc-
clusion rates in relation to blood glucose on admis-
sion. Angiographic data is presented in Table 2.
In-hospital and 1-year follow-up. Patients with
hyperglycemia had greater myocardial infarct extent
according to creatine kinase level (2611.11 IU/L
vs. 1923.81 IU/L) and lower left ventricular ejection
fraction (44.85% vs. 46.57%) in comparison to tho-
se without hyperglycemia. Higher levels of myocar-
dial enzymes and lower left ventricular ejection
fraction correlated with higher mortality rate. In the
hyperglycemic subgroup, the in-hospital mortality
rate was about 6-times higher than in the group of
patients without hyperglycemia (3.44% vs. 0.52%).
In-hospital mortality in the non-DM group was
1.7%. Moreover, patients with hyperglycemia sho-
wed a higher 1-year mortality rate compared to non-
hyperglycemic (8.51% vs. 3.68%, respectively).
One-year mortality in all patients without DM was
5.6%. Additionally, in 1-year follow-up, the hyper-
glycemic subgroup showed higher stroke (1.86% vs.
0.35%) and MACE rates (14.89% vs. 8.95%). The
data on in-hospital and long-term follow-up are pre-
sented in Table 3.
Predictors of higher 1-year mortality.
Multivariate analysis. Multivariate analysis re-
vealed that in the group of patients without DM,
Table 3. In-hospital and 1-year observation of analyzed groups.
Parameters Patients with diabetes mellitus Patients without diabetes mellitus
                              Blood glucose level p                     Blood glucose level p
< 7.8 mmol/L ≥ 7.8 mmol/L < 7.8 mmol/L ≥ 7.8 mmol/L
(140 mg/dL) (140 mg/dL) (140 mg/dL) (140 mg/dL)
Maximum CK 1778.76 ± 2289.52 ± 0.14 1923.81 ± 2611.11 ± 0.000004
concentration [IU/L] ± 1373.05 ± 2081.30 ± 1588.53  ± 2178.35
LVEF [%] 43.16 ± 7.77 43.01 ± 8.60 0.89 46.57 ± 7.3 44.85±7.1 0.0005
Gastrointestinal 1.59 1.04 0.70 0.69 0.80 0.85
bleeding [%]
Hemorrhagic 1.59 2.42 0.13 1.03 1.06 0.37
complications
requiring packed
red blood cells [%]
Urgent CABG [%] 3.17 5.54 0.44 5.17 4.76 0.77
In-hospital stroke [%] 0.00 1.73 0.29 0.86 2.38 0.16
In-hospital mortality [%] 7.94 8.3 0.92 0.52 3.44 0.001
Mean time of 9.33 ± 6.53 9.24 ± 5.06 0.85 8.33 ± 3.88 8.64 ± 4.84 0.23
hospitalization [days]
Stroke in 1-year 1.59 2.09 0.19 0.35 1.86 0.04
follow-up [%]
Reinfarction in 4.76 5.92 0.44 5.44 6.38 0.45
1-year follow-up [%]
1-year mortality [%] 11.11 17.07 0.14 3.68 8.51 0.001
MACE in 1-year 17.46 23.34 0.30 8.95 14.89 0.0047
follow-up [%]
CK — creatine kinase; LVEF — left ventricular ejection fraction; CABG — coronary artery bypass grafting; MACE — major adverse cardiovascular events
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blood glucose level on admission (per 1 mmol/L)
was the factor affecting 1-year mortality (HR =
= 1.09; 95% CI 1.01–1.17). Patients’ age, stent im-
plantation and left ventricular ejection fraction were
also significant. Table 5 presents the results of mul-
tivariate analysis.
Discussion
The mechanisms behind elevated blood gluco-
se levels in the acute phase of myocardial infarc-
tion are not clearly identified. However, it is hypo-
thesized that peri-infarction stress and concomitant
increased adrenergic stimulation are the cause [13, 21].
Moreover, myocardial infarction may be a trigger
revealing pre-existing impaired glucose tolerance
or DM [22, 23]. Threshold values for hyperglyce-
mia in acute myocardial infarction are very diver-
sely defined in literature [8–12, 16]. Assuming the
blood glucose level to be a risk factor, the asses-
sment of a predictive value of glucose levels in the
acute myocardial infarction phase is worth attention.
The authors of this report defined hyperglycemia
in acute myocardial infarction phase to be ≥ 7.8 mmol/L
(140 mg/dL). The accepted level is convergent with
other authors’ reports [16, 17]. Moreover, this
Table 4. Predictors of 1-year mortality in patients with myocardial infarction and diabetes mellitus.
Multivariate analysis.
Parameters Hazard ratio 95% CI P
Initial TIMI 0–1 flow 2.03 1.09–4.55 0.04
Hypertension 1.49 0.78–2.84 0.22
Age [per 10 years] 1.33 0.95–1.84 0.08
Prior myocardial infarction 1.28 0.70–2.31 0.40
Anterior infarction 1.12 0.62–2.02 0.68
Females 1.12 0.62–2.01 0.69
Smokers 1.06 0.55–2.04 0.84
Blood glucose level [per 1 mmol/L] 1.03 0.98–1.08 0.26
Time from onset of symptoms to PCI [per 1 h] 0.98 0.94–1.03 0.58
Multivessel coronary disease 0.93 0.51–1.74 0.84
Final TIMI 3 flow 0.85 0.41–1.78 0.67
Stenting 0.84 0.45–1.56 0.58
Left ventricular ejection fraction [per 10%] 0.47 0.34–0.64 < 0.0001
PCI — percutaneous coronary intervention; TIMI — thrombolysis in myocardial infarction; CI — confidence interval
Table 5. Predictors of 1-year mortality in patients with myocardial infarction without diabetes mellitus.
Multivariate analysis.
Parameters Hazard ratio 95% CI P
Age [per 10 years] 1.74 1.33–2.27 < 0.0001
Multivessel coronary disease 1.51 0.83–2.74 0.17
Initial TIMI 0–1 flow 1.41 0.68–2.93 0.34
Smokers 1.39 0.78–2.48 0.26
Blood glucose level [per 1 mmol/L] 1.09 1.01–1.17 0.04
Time from onset of symptoms to PCI [per 1 h] 1.01 0.96–1.05 0.74
Females 0.92 0.48–1.76 0.80
Final TIMI 3 flow 0.91 0.42–2.00 0.82
Hypertension 0.88 0.51–1.50 0.64
Anterior infarction 0.85 0.49–1.47 0.57
Prior myocardial infarction 0.57 0.27–1.19 0.13
Stenting 0.49 0.25–0.96 0.03
Left ventricular ejection fraction [per 10%] 0.46 0.34–0.64 <0.0001
PCI — percutaneous coronary intervention; TIMI —thrombolysis in myocardial infarction; CI — confidence interval
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cut-off point is recommended by worldwide stan-
dards for a 2-hour glucose tolerance test, a tool for
carbohydrate metabolism disorder diagnosis [24–
26]. Because of a possible linear relationship betwe-
en blood glucose and mortality, in our multivariate
analysis, admission glucose concentration was used
as a continuous variable.
Patients with diabetes mellitus
This analysis did not confirm that glucose le-
vels during the acute phase of STEMI in patients
with DM treated with PCI is connected with a hi-
gher in-hospital and 1-year mortality rate. This may
be due to the similarity of initial and final IRA flow,
maximum myocardial damage enzyme levels and
left ventricular ejection fraction in both subgroups.
These are important conclusions, since the multi-
variate analysis results show that the death risk in
1-year follow-up was influenced by left ventricular
ejection fraction and initial infarction-related arte-
ry flow. Despite the differences of age in the sub-
group with and without hyperglycemia, age was not
an independent predictor of 1-year mortality in
multivariate analysis adjusted for other risk factors.
Results consistent with the mentioned analysis,
namely the lack of a relationship between blood glu-
cose on admission and prognosis of patients with
diabetes mellitus, and myocardial infarction were
presented by Foo et al. [11]. The nationwide CCP
(Cooperative Cardiovascular Project) register inc-
luded data of patients hospitalized due to myocar-
dial infarction treated with fibrinolytic therapy or
PCI. The analysis showed that the 30-day and
1-year mortality in patients with DM is independent
on blood glucose on admission [12]. Nevertheless,
there are also some reports contradicting our ana-
lysis, suggesting that prognosis of DM patients may
be derived from blood glucose during the acute
myocardial infarction phase. Ishihara et al. [27] pre-
sented a 2-fold higher hospital mortality rate in the
subgroup of patients with DM and hyperglycemia
in comparison to patients with DM without hyper-
glycemia. Likewise, Cao et al. [9] reported higher
in-hospital mortality rate in the group of patients
with DM and hyperglycemia. Multivariate analysis
showed 5-fold risk of death in patients with hyper-
glycemia over 300 mg/dL and 2.8-fold in patients
with hyperglycemia over 218 mg/dL, in comparison
to patients with blood glucose level below 161 mg/dL.
The meta-analysis performed by Capes et al. [8] pre-
sented higher in-hospital death risk of patients with
DM and hyperglycemia in comparison to patients wi-
thout hyperglycemia. It should be emphasized that the
mentioned meta-analysis included patients treated
with fibrinolysis or conservative therapy. Similarly,
in the DIGAMI study (The Diabetes and Insulin-Glu-
cose Infusion in Acute Myocardial Infarction), fibrino-
lytic therapy was used as a reperfusion method. No-
netheless, admission blood glucose level was an in-
dependent factor determining long-term mortality
rate [13]. Svensson et al. [10] analyzed a group of pa-
tients with acute coronary syndromes (unstable an-
gina — 36.75%, myocardial infarction — 63.25%) with
concomitant DM and demonstrated an analogical re-
lationship in 30-day and 2-year follow-up..
Patients without diabetes
In this study, blood glucose levels in acute
myocardial infarction in patients without DM, unli-
ke patients with diabetes, appeared to have a signi-
ficant influence on prognosis. Blood glucose levels
on admission were a significant factor determining
1-year mortality. The above relationship was con-
firmed in other reports. In the already cited meta-
analysis by Capes et al. [8], in-hospital death risk
of patients without DM was about 4-times higher
in patients with hyperglycemia than in those witho-
ut hyperglycemia. The ICONS (Improving Cardio-
vascular Outcomes in Nova Scotia) registry showed
significantly higher in-hospital mortality in patients
without DM and hyperglycemia than in the rest of
this non-DM group. In addition, multivariate ana-
lysis showed that the relative risk of death (in
a group of patients without DM and with hyperglyce-
mia vs. patients without DM and without hyperglyce-
mia) was odds ratio — OR = 2.44 (1.42–4.2) [14].
The CCP registry showed that patients without DM
and elevated blood glucose during acute myocardial
infarction presented increased 30-day and 1-year
mortality rates in relation to patients with DM [12].
Timmer et al. [17] analyzed 356 consecutive pa-
tients without DM with myocardial infarction tre-
ated with primary PCI or fibrinolysis and showed an
8-year mortality rate that differed significantly in the
groups of blood glucose < 7.8 mmol/L, ≥ 7.8–
–11.0 mmol/L and ≥ 11.1 mmol/L. Additionally, they
proved in multivariate analysis that blood glucose
levels on admission were an independent late morta-
lity factor. Our analysis of composite endpoint (death,
reinfarction and stroke) revealed higher occurrence
in the subgroup of patients without DM and with
concomitant hyperglycemia. Norhammar et al.  [18]
reported similar results. They demonstrated that
every 3 mmol/L rise in glucose levels is associated
with an increased risk of death, reinfarction or con-
gestive heart failure OR = 1.24 (1.08–1.54). In our
analysis, the prognosis of patients without DM with
concomitant hyperglycemia may, in part, be explained
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by the following differences in group characteristics.
For one, patients with hyperglycemia were gene-
rally > 60 years of age, which agreed with a multi-
variate analysis showing that age was an indepen-
dent factor of increased mortality rate in 1-year
follow up. In addition, patients without DM with hy-
perglycemia showed an increased rate of inefficient
fibrinolysis and the presence of multivessel coro-
nary heart disease. The patients without DM with
hyperglycemia differed not only in the mentioned
parameters, but also in infarction severity by the
concentration of myocardial necrotic markers and
left ventricular ejection fraction. The subgroup of
patients with hyperglycemia had elevated myocar-
dial necrotic markers and lower left ventricular ejec-
tion fraction. This may be relevant since ejection
fraction was an independent risk factor determining
1-year mortality in multivariate analysis. Higher
myocardial necrotic markers and lower left ventri-
cular ejection fraction in patients without DM and
with hyperglycemia were also reported by Timmer
et al. [17]. Ishihara et al. [28], in their analysis of
529 consecutive patients with anterior wall myocar-
dial infarction treated with PCI or fibrinolytic the-
rapy, found that the left ventricular ejection frac-
tion was significantly lower in the subgroup with
hyperglycemia, compared to the group without hy-
perglycemia. Left ventricular ejection fraction re-
covery, measured as DWMS (wall motion score in-
dex), was demonstrated to be lower in patients with
hyperglycemia [29]. Of note, in our study, despite
the higher mortality rate of non-DM patients with
hyperglycemia, this group consisted of more fema-
les, less smokers and patients with shorter pain
duration than the non-hyperglycemia group.
Limitations of the study
This study is a retrospective analysis based on
the results from a single centre registry. Glycosy-
lated hemoglobin (HbA1c) levels in acute myocar-
dial infarction, which would allow the assessment
glucose metabolism prior to infarction and deter-
mination of its prognostic meaning, were not asses-
sed. Due to the character of the analysis, the oc-
currence of diabetes that could emerge after myo-
cardial infarction was not estimated.
Conclusions
Elevated blood glucose levels in acute myocar-
dial infarction affect the prognosis of patients wi-
thout diabetes mellitus; however, it is not an inde-
pendent risk factor of fatal outcome in patients with
diabetes treated with PCI.
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